➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Medtronic
McKesson
McKinsey
Merck

Last Updated: January 19, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for PU-H71

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug PU-H71?

PU-H71 is an investigational drug.

There have been 4 clinical trials for PU-H71. The most recent clinical trial was a Phase 1 trial, which was initiated on May 1st 2019.

The most common disease conditions in clinical trials are Thrombocytosis, Lymphoma, and Thrombocythemia, Essential. The leading clinical trial sponsors are Memorial Sloan Kettering Cancer Center, Samus Therapeutics, Inc., and National Cancer Institute (NCI).

There are one hundred and ten US patents protecting this investigational drug and six hundred and forty-five international patents.

Recent Clinical Trials for PU-H71
TitleSponsorPhase
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking RuxolitinibSamus Therapeutics, Inc.Phase 1
PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast CancerSamus Therapeutics, Inc.Phase 1
PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast CancerMemorial Sloan Kettering Cancer CenterPhase 1

See all PU-H71 clinical trials

Clinical Trial Summary for PU-H71

Top disease conditions for PU-H71
Top clinical trial sponsors for PU-H71

See all PU-H71 clinical trials

US Patents for PU-H71

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PU-H71   Start Trial Small-molecule Hsp90 inhibitors Sloan-Kettering Institute for Cancer Research (New York, NY)   Start Trial
PU-H71   Start Trial Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy University of Georgia Research Foundation Inc. (Athens, GA)   Start Trial
PU-H71   Start Trial Constructs targeting AFP peptide/MHC complexes and uses thereof EUREKA THERAPEUTICS, INC. (Emeryville, CA)   Start Trial
PU-H71   Start Trial Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta Berg LLC (Nashville, TN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PU-H71

Drugname Country Document Number Estimated Expiration Related US Patent
PU-H71 World Intellectual Property Organization (WIPO) WO2006084030 2025-02-01   Start Trial
PU-H71 European Patent Office EP3016715 2033-07-01   Start Trial
PU-H71 Japan JP2016523926 2033-07-01   Start Trial
PU-H71 World Intellectual Property Organization (WIPO) WO2015002996 2033-07-01   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Medtronic
McKesson
McKinsey
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.